Patents by Inventor Dawn Marchadier

Dawn Marchadier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol
    Publication number: 20130059361
    Abstract: Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.
    Type: Application
    Filed: December 12, 2011
    Publication date: March 7, 2013
    Inventors: Michael Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South, Dawn Marchadier, Cyrille Maugeais, Daniel J. Rader
  • Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol
    Publication number: 20090208479
    Abstract: Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.
    Type: Application
    Filed: August 25, 2008
    Publication date: August 20, 2009
    Inventors: Michael Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South, Dawn Marchadier, Cyrille Maugeais, Daniel J. Rader
  • Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein Al, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
    Publication number: 20060088504
    Abstract: Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 27, 2006
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Michael Jaye, Kim-Anh Doan, John Krawiec, Kevin Lynch, Dilip Amin, Victoria South, Dawn Marchadier, Cyrille Maugeais, Daniel Rader
  • Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
    Patent number: 7008776
    Abstract: The present invention relates to compositions for use in raising or lowering the level of LIPG polypeptide in a patient. Embodiments of the composition include compositions comprising: an anti-sense nucleic acid; a neutralizing antibody; an intracellular binding protein; an inhibitor which inhibits the enzymatic activity of LIPG polypeptide; an inhibitor which inhibits the expression of LIPG gene; a ribozyme; an LIPG polypeptide; an enhancer which increases the enzymatic activity of LIPG polypeptide; or an enhancer which increases the expression of LIPG gene. The invention relates also to methods for using the above compositions. In addition, the invention relates to a method for diagnosing a predisposition to lower cholesterol, a method for determining whether a test compound can inhibit the enzymatic reaction between LIPG polypeptide and HDL cholesterol, and methods for determining whether a test compound can enhance the enzymatic reaction between LIPG polypeptide and LDL or VLDL cholesterol.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: March 7, 2006
    Assignees: Aventis Pharmaceuticals Inc., The Trustees of the University of Pennsylvania
    Inventors: Michael Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South, Dawn Marchadier, Cyrille Maugeais, Daniel J. Rader